The Shotlee Journal
Browse Shotlee articles about GLP-1 Medications.
Showing 9 / 939 GLP-1 Medications articles
The Real Housewives of Salt Lake City star Heather Gay's face looks more voluminous at 49 than at 38, thanks to a series of cosmetic procedures—and a touch of Ozempic face. From Botox in her 30s to collagen stimulation now, her story highlights the blend of aesthetics and GLP-1 side effects. See how she navigated it all.
Just 20% of youth eligible for GLP-1 receptor agonists due to obesity are actually prescribed these medications, according to a recent Pediatrics study. Prescribing favors older adolescents with higher BMI and specific racial groups, but interruptions due to cost affect nearly two-thirds. This highlights gaps in access to promising obesity treatments for teens.
A Rhode Island mother battled alcoholism for years, losing custody of her son, until GLP-1 drugs like Wegovy and Mounjaro helped curb her cravings in a pilot program. Gina Roberts shares her journey to two years sober, her own apartment, and family reunion. Addiction specialist Dr. Steven Klein discusses the promising role of these medications alongside traditional supports.
Weight-loss injections like Ozempic and Wegovy, containing semaglutide, may protect the heart from severe tissue damage after a heart attack, according to new research. The study reveals how this GLP-1 medication prevents the dangerous 'no-reflow' phenomenon. Experts suggest it could even be administered by paramedics en route to the hospital.
Despite fears that surging GLP-1 weight loss drugs would slash snack sales, new USDA data shows units holding steady at over 10 billion annually through 2024. Prescriptions rose from 0.5% to 2% of adults, yet food consumption patterns surprise economists. Discover the resilience, consumer shifts, and future outlook.
Obesity levels have plateaued in Denmark at 18.5% among adults and older teens in 2025, unchanged from 2021 after years of rises from 13.6% in 2010. Novo Nordisk launched Wegovy there in late 2022, with 270,000 users—nearly 5% of the population—potentially shifting trends away from 32% by 2040 projections. Experts credit GLP-1 drugs like Wegovy and Ozempic alongside lifestyle factors.
A man who shed six stone on Mounjaro shares his dramatic transformation from 123kg, but warns of 'horrible' side effects like chronic vomiting and dehydration no one mentioned. Despite the challenges, he reduced hypertension meds and gained food control. Discover his full story and management strategies.
Patients on GLP-1 drugs report losing cravings not just for food, but for cigarettes, alcohol, and more—without effort. A new study of over 600,000 people confirms dramatic reductions in overdoses, deaths, and new addictions. Could semaglutide and tirzepatide redefine addiction care?
New research tracking nearly 150,000 people on GLP-1 medications like Ozempic and Wegovy suggests higher risks of osteoporosis, gout, and osteomalacia over five years. While not proving causation, the study highlights potential impacts on bone and joint health from rapid weight loss. Experts emphasize nutrition, exercise, and monitoring to mitigate risks.
